|
WO2011139652A1
|
|
Selective enrichment of cpg islands
|
|
WO2011142952A1
|
|
Method of detecting and profiling progression of the risk of neurodegenerative diseases
|
|
WO2011046700A1
|
|
Cftr-activating enhancer
|
|
WO2011009107A2
|
|
Animal models of neurological disorders
|
|
WO2008014426A2
|
|
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
|
WO2008010928A2
|
|
Method for discovery of anti-senescence genes
|
|
WO2007100765A2
|
|
Lysozyme-modified probiotic components and uses thereof
|
|
WO2006068742A2
|
|
Use of cathepsin inhibitors for reversing or preventing resistance of a cancer cell to a cytotoxic agent
|
|
WO2006039253A2
|
|
Sirna-mediated gene silencing of alpha synuclein
|
|
WO2005116224A2
|
|
Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
|
|
US2005215959A1
|
|
Delivery devices and methods of delivering liquids and nutrition to patients
|
|
AU2606002A
|
|
Compositions containing gangliosides for use in the treatment of skin disorders
|
|
US4112926A
|
|
Method and apparatus for measuring and treating hyperactivity in human beings
|
